REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Regenxbio (RGNX) Misses Q1 EPS by 21c, Revenues Miss
May 7, 2020 5:36 PM EDTRegenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.08), $0.21 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $17.64 million versus the consensus estimate of $18.45 million.
"Our overall focus at REGENXBIO during the COVID-19... More
